Articles Links

New study on Nalmefene

Abstract

Objectives To determine whether nalmefene combined with psychosocial support is cost-effective compared with psychosocial support alone for reducing alcohol consumption in alcohol-dependent patients with high/very high drinking risk levels (DRLs) as defined by the WHO, and to evaluate the public health benefit of reducing harmful alcohol-attributable diseases, injuries and deaths.

Design Decision modelling using Markov chains compared costs and effects over 5 years.

Setting The analysis was from the perspective of the National Health Service (NHS) in England and Wales.

Participants The model considered the licensed population for nalmefene, specifically adults with both alcohol dependence and high/very high DRLs, who do not require immediate detoxification and who continue to have high/very high DRLs after initial assessment.

Data sources We modelled treatment effect using data from three clinical trials for nalmefene (ESENSE 1 (NCT00811720), ESENSE 2 (NCT00812461) and SENSE (NCT00811941)). Baseline characteristics of the model population, treatment resource utilisation and utilities were from these trials. We estimated the number of alcohol-attributable events occurring at different levels of alcohol consumption based on published epidemiological risk-relation studies. Health-related costs were from UK sources.

Main outcome measures We measured incremental cost per quality-adjusted life year (QALY) gained and number of alcohol-attributable harmful events avoided.

Results Nalmefene in combination with psychosocial support had an incremental cost-effectiveness ratio (ICER) of £5204 per QALY gained, and was therefore cost-effective at the £20 000 per QALY gained decision threshold. Sensitivity analyses showed that the conclusion was robust. Nalmefene plus psychosocial support led to the avoidance of 7179 alcohol-attributable diseases/injuries and 309 deaths per 100 000 patients compared to psychosocial support alone over the course of 5 years.

Conclusions Nalmefene can be seen as a cost-effective treatment for alcohol dependence, with substantial public health benefits.

Trial registration numbers This cost-effectiveness analysis was developed based on data from three randomised clinical trials: ESENSE 1 (NCT00811720), ESENSE 2 (NCT00812461) and SENSE (NCT00811941).

CALL ME FOR A FREE CONSULTATION

MICHAEL SHULTZ


SERVING CLIENTS IN SOUTHERN
CALIFORNIA COURTS FOR OVER 30 YEARS
CALL FOR DETAILS
(310) 456-1913
Free Consultation

FREE CONSULTATION!

Name*:
Email*:
Phone:
Any Questions or Comments? (optional):
2+5=* So we know you are human.
MICHAEL L. SHULTZ, ATTORNEY AT LAW

MEMBER OF THE CALIFORNIA
STATE BAR SINCE DEC 1972
SBN# 054551


Web Design By The Web Corner